Risk of unexpected adverse effects and product liability claims
First written in FY2019. 2 of 4 entries say "Restated". Latest entry: FY2026.
The whole theme swung hardest in 2026: 6 of 20 companies on the "Worse" side.
36 other companies' latest entry also says "Restated".
- FY2026RestatedAnnual report
「We maintain appropriate insurance covering various liabilities, including product liability, to prepare for such events. However, there is no guarantee that insurance proceeds will cover the full amount of any damages ultimately borne by the company.」
副作用・製造物責任への対応として保険に加入しつつ、補償額全額の支払いは保証されないとのリスク認識を再確認している。 - FY2025Insurance coverage and limits of compensation specifiedAnnual report
「We maintain appropriate insurance covering various liabilities, including product liability, to prepare for such events. However, there is no guarantee that insurance proceeds will cover the full amount of any damages ultimately borne by the company.」
副作用・製造物責任リスクへの対応として適切な保険への加入を明示する一方、賠償額全額が補償される保証はないと記載した。 - FY2022RestatedAnnual report
「Medicines may produce unexpected adverse effects from the clinical-trial stage through and after commercial launch.」
臨床試験段階から上市後までの予期せぬ副作用・製造物責任リスクを再確認している。 - FY2019First statedAnnual report
「Medicines may produce unexpected adverse effects from the clinical-trial stage through and after commercial launch.」
臨床試験段階から上市後まで、予期せぬ副作用や製造物責任請求が発生する可能性をリスクとして記載している。